{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06464367",
            "orgStudyIdInfo": {
                "id": "2000034634"
            },
            "secondaryIdInfos": [
                {
                    "id": "ES0006",
                    "type": "OTHER",
                    "domain": "VA Connecticut Healthcare System"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "Mechanistic Studies of Psilocybin in Headache Disorders",
            "officialTitle": "Mechanistic Studies of Psilocybin in Headache Disorders",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "mechanistic-studies-of-psilocybin-in-headache-disorders"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-08",
            "studyFirstSubmitQcDate": "2024-06-12",
            "studyFirstPostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Emmanuelle Schindler",
                "investigatorTitle": "Assistant Professor of Neurology",
                "investigatorAffiliation": "Yale University"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Wallace Research Foundation",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the administration of psilocybin or an active control agent."
        },
        "conditionsModule": {
            "conditions": [
                "Migraine"
            ],
            "keywords": [
                "psilocybin",
                "resting state functional connectivity",
                "synaptic density",
                "synaptic vessel glycoprotein 2A (SV2A)",
                "circadian rhythm",
                "sleep",
                "inflammation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Migraine psilocybin",
                    "type": "EXPERIMENTAL",
                    "description": "Migraine participants randomized to receive 10 mg psilocybin (oral)",
                    "interventionNames": [
                        "Drug: Psilocybin"
                    ]
                },
                {
                    "label": "Migraine placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Migraine participants randomized to receive 2.5 mg THC (oral)",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Healthy control psilocybin",
                    "type": "EXPERIMENTAL",
                    "description": "Healthy control participants randomized to receive 10 mg psilocybin (oral)",
                    "interventionNames": [
                        "Drug: Psilocybin"
                    ]
                },
                {
                    "label": "Healthy control placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Healthy control participants randomized to receive 2.5 mg THC",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Psilocybin",
                    "description": "synthetic psilocybin 10 mg (oral)",
                    "armGroupLabels": [
                        "Healthy control psilocybin",
                        "Migraine psilocybin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "synthetic THC 2.5 mg (oral)",
                    "armGroupLabels": [
                        "Healthy control placebo",
                        "Migraine placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Baseline SV2A PET",
                    "description": "Comparing initial SV2A PET between migraine and HC",
                    "timeFrame": "from date of randomization until the date of first PET scan, assessed up to 6 months"
                },
                {
                    "measure": "Baseline RSFC",
                    "description": "Comparing initial RSFC between migraine and HC",
                    "timeFrame": "from date of randomization until the date of first MRI, assessed up to 6 months"
                },
                {
                    "measure": "Change in SV2A PET after drug administration",
                    "description": "Comparing change in SV2A PET after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from date of first PET scan to the date of second PET scan, assessed up to 6 months"
                },
                {
                    "measure": "Change in resting state functional connectivity (RSFC) after drug administration",
                    "description": "Comparing change in RSFC after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from date of first MRI to the date of second MRI, assessed up to 6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in TNF-alpha",
                    "description": "Comparing change in TNF-alpha levels after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in IL-1beta",
                    "description": "Comparing change in IL-1beta levels after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in IL-6",
                    "description": "Comparing change in IL-6 levels after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in calcitonin gene-related peptide (CGRP)",
                    "description": "Comparing change in CGRP levels after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in pituitary adenylate cyclase activating polypeptide (PACAP)",
                    "description": "Comparing change in PACAP levels after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in bedtime (via actigraphy)",
                    "description": "Comparing change in bedtime (time) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening through 14 days after drug administration"
                },
                {
                    "measure": "Change in get-up time (via actigraphy)",
                    "description": "Comparing change in get-up time (time) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening through 14 days after drug administration"
                },
                {
                    "measure": "Change in daily active period (via actigraphy)",
                    "description": "Comparing change in daily active period (hours) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening through 14 days after drug administration"
                },
                {
                    "measure": "Change in daily rest period (via actigraphy)",
                    "description": "Comparing change in daily rest period (hours) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening through 14 days after drug administration"
                },
                {
                    "measure": "Change in REM latency (via sleep electroencephalography)",
                    "description": "Comparing change in REM latency (minutes) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in percent REM (via sleep electroencephalography)",
                    "description": "Comparing change in percent REM (%) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Change in sleep efficiency (via sleep electroencephalography)",
                    "description": "Comparing change in sleep efficiency (%) after drug between psilocybin/THC and migraine/HC",
                    "timeFrame": "from screening to 7 days after drug administration"
                },
                {
                    "measure": "Adverse events",
                    "description": "Adverse events from any procedure or drug administration",
                    "timeFrame": "from screening through 3 months after drug administration"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Acute change in TNF-alpha during drug administration",
                    "description": "Comparing change in TNF-alpha between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 120, and 240 minutes after drug administration"
                },
                {
                    "measure": "Acute change in IL-1beta during drug administration",
                    "description": "Comparing change in IL-1beta between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 120, and 240 minutes after drug administration"
                },
                {
                    "measure": "Acute change in IL-6 during drug administration",
                    "description": "Comparing change in IL-6 between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 120, and 240 minutes after drug administration"
                },
                {
                    "measure": "Acute change in calcitonin gene related peptide (CGRP) during drug administration",
                    "description": "Comparing change in CGRP between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 120, and 240 minutes after drug administration"
                },
                {
                    "measure": "Acute change in pituitary adenylate cyclase activating polypeptide (PACAP) during drug administration",
                    "description": "Comparing change in PACAP between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 120, and 240 minutes after drug administration"
                },
                {
                    "measure": "Acute change in mean arterial pressure (MAP) during drug administration",
                    "description": "Comparing change in MAP (mmHg) between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 30, 60, 120, 180, 240, 300, and 360 minutes after drug administration"
                },
                {
                    "measure": "Acute change in heart rate during drug administration",
                    "description": "Comparing change in heart rate (beats per minute) between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 30, 60, 120, 180, 240, 300, and 360 minutes after drug administration"
                },
                {
                    "measure": "Acute change in SpO2 during drug administration",
                    "description": "Comparing change in SpO2 (%) between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 30, 60, 120, 180, 240, 300, and 360 minutes after drug administration"
                },
                {
                    "measure": "Acute change in general drug effects during drug administration",
                    "description": "Comparing \"overall,\" \"anxiety/fear,\" \"sleepiness/sedation,\" \"nausea,\" \"joy/intense happiness,\"\"peace/harmony\" between psilocybin/THC and migraine/HC",
                    "timeFrame": "0, 30, 60, 120, 180, 240, 300, and 360 minutes after drug administration"
                },
                {
                    "measure": "Acute psychedelic effects during drug administration",
                    "description": "Comparing 5-Dimensional Altered States of Consciousness scale scores (0-100; higher score being more psychedelic) between psilocybin/THC and migraine/HC",
                    "timeFrame": "up to 8 hours after drug administration"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\n* Age 21 to 70 (inclusive)\n* Migraine disease per ICHD-3 criteria (for migraine participants) OR Healthy control patient\n\nExclusion criterion\n\n* Unstable medical condition or serious nervous system pathology\n* Pregnant, breastfeeding, lack of adequate birth control\n* Psychotic or manic disorder\n* Substance abuse in the prior 3 months\n* Use of classic psychedelics (e.g., psilocybin, LSD, mescaline) in the past 6 months\n* Use of cannabis or other THC products in the prior 2 weeks\n* Urine toxicology positive to drugs of abuse\n* The use of triptans (e.g., sumatriptan) or ditans (e.g., lasmiditan) more than twice weekly on average\n* Use of serotonergic preventive therapies (i.e., taken chronically; amitriptyline, fluoxetine, imipramine, cyproheptadine) in the past 6 weeks\n* Use of preventive or transitional treatments that produce spikes and waning of symptom relief (e.g., botulinum toxin, calcitonin gene-related peptide system targeting antibodies, peripheral nerve or ganglion blocks, chiropractic manipulation)\n* History of a bleeding disorder or are currently taking anticoagulants (e.g., warfarin, enoxaparin, dabigatran, apixaban).\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen) in the 7 days before PET scan and 7 days after PET scan.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Heather Garrett, BS",
                    "role": "CONTACT",
                    "phone": "203-937-5711",
                    "phoneExt": "1-2406",
                    "email": "heather.garrett@yale.edu"
                },
                {
                    "name": "Emmanuelle Schindler, MD, PhD",
                    "role": "CONTACT",
                    "phone": "203-932-5711",
                    "phoneExt": "1-4335",
                    "email": "emmanuelle.schindler@yale.edu"
                }
            ],
            "locations": [
                {
                    "facility": "VA Connecticut Healthcare System",
                    "city": "West Haven",
                    "state": "Connecticut",
                    "zip": "06516",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Garrett, B.S.",
                            "role": "CONTACT",
                            "phone": "203-932-5711",
                            "phoneExt": "1-2406",
                            "email": "heather.garrett@yale.edu"
                        },
                        {
                            "name": "Emmanuelle Schindler, MD, PhD",
                            "role": "CONTACT",
                            "phone": "203-932-5711",
                            "phoneExt": "1-4335",
                            "email": "emmanuelle.schindler@yale.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.27065,
                        "lon": -72.94705
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000020773",
                    "term": "Headache Disorders"
                },
                {
                    "id": "D000006261",
                    "term": "Headache"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "relevance": "LOW"
                },
                {
                    "id": "M9351",
                    "name": "Headache",
                    "asFound": "Headache",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11852",
                    "name": "Migraine Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M22529",
                    "name": "Headache Disorders",
                    "asFound": "Headache Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011562",
                    "term": "Psilocybin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006213",
                    "term": "Hallucinogens"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14419",
                    "name": "Psilocybin",
                    "asFound": "Mild to Moderate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M340819",
                    "name": "polysaccharide-K",
                    "relevance": "LOW"
                },
                {
                    "id": "M9305",
                    "name": "Hallucinogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}